SWE, an squalene-in-water emulsion adjuvant in open-access, for the benefit of the entire vaccine community. SQ, LQ, LMQ are also available at GMP grade upon request

The development of SWE started with the support of various funders, such as the European Commission, US HHS-BARDA, the German Government Technical Cooperation.

VFI has transferred manufacturing processes and quality control of SWE to vaccine manufacturers in developing countries: PT Biofarma in Indonesia and IVAC in Vietnam.

Over the years, SWE was demonstrated safe and effective, both in terms of enabling adjuvanticity and dose-sparing, when included in numerous preclinical vaccine candidates, including against Inactivated Polio Virus, Influenza, Respiratory Syncytial Virus, Rabies, and Group A streptococcus.